Previous 10 | Next 10 |
Jounce Therapeutics, Inc. (JNCE) Q4 2019 Results Conference Call February 27, 2020 08:00 AM ET Company Participants Komal Joshi - Investor Relations Rich Murray - Chief Executive Officer & President Beth Trehu - Chief Medical Officer Kim Drapkin - Chief Financial Officer ...
Jounce Therapeutics (NASDAQ: JNCE ): Q4 GAAP EPS of -$0.68 misses by $0.40 . More news on: Jounce Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in cash, cash equivalents and investments - - Company to host conference call and webcast tod...
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming inve...
CAMBRIDGE, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2019 fi...
Today, we will study why Jounce Therapeutics ( JNCE ) is an attractive pick in 2020. Company overview Jounce Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies targeting different immune cell types within the tumor microenviro...
- Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TIS vopra ) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit in patients from the ICONIC trial - - Research collaboration establi...
Jounce Therapeutics (JNCE) is a biotech that should be on your radar in the coming weeks. That's because it is set to present new data from the ICONIC trial for its vopratelimab drug to treat patients with advanced solid tumors. This presentation will pretty much show why an RNA signature ...
CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Robert Iannone, M.D., M.S.C.E., to it...
CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and ...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...